Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalOncologyColorectal CancerOther

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

The identification of risk factors for second primary cancers in colorectal cancer survivors is critical for developing targeted surveillance strategies. This can significantly influence treatment protocols and patient management within oncology portfolios.

Published: June 17, 2026
Updated: June 17, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Colorectal Cancer
Company: Pfizer
Asset: Keytruda
Indication: colorectal cancer
Trial SummaryCLN

Phase III

colorectal cancer

Status

Active

Sponsor

Pfizer

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The identification of risk factors for second primary cancers in colorectal cancer survivors is critical for developing targeted surveillance strategies. This can significantly influence treatment protocols and patient management within oncology portfolios.

Why it matters

The identification of risk factors for second primary cancers in colorectal cancer survivors is critical for developing targeted surveillance strategies. This can significantly influence treatment protocols and patient management within oncology portfolios.

What changed

Other

Analysis

The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.

The identification of risk factors for second primary cancers in colorectal cancer survivors is critical for developing targeted surveillance strategies. This can significantly influence treatment protocols and patient management within oncology portfolios.

Monitor developments in surveillance guidelines and potential new therapies targeting second primary cancers in CRC survivors.

Related companies & assets

Companies

  • Pfizer →

Assets

  • Keytruda →
  • Oncology →

Sources & Humanexa intelligence

Source links

  • Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center ↗
  • Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors ↗

Related Humanexa pages

  • Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors →

Related signals

Trial SummaryCLN

Phase III

gastric cancer therapies

Status

Active

Signal Score

8.4

Clinicalhigh signal

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

epithelial ovarian cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.